# Clinical Outcomes Data for Azacitidine in CMML

## Structured Data Table

| Efficacy Measure | Value | Citation |
|-----------------|-------|----------|
| Complete Response | 14.5 | PMID: 36455187 |
| Partial Response | 23.7 | PMID: 40252309 |
| Marrow Cr | 22.1 | PMID: 37548390 |
| Progression Free Survival | 7.3 | PMID: 38895081 |
| Overall Survival | 14.9 | PMID: 40252309 |
| Event Free Survival | 12.1 | PMID: 36455187 |
| Grade 3-4 Neutropenia | 19.2% | PMID: 40252309 |
| Grade 3-4 Thrombocytopenia | 12.8% | PMID: 37548390 |
| Febrile Neutropenia | 8.4% | PMID: 38895081 |

## Drug Summary

Azacitidine demonstrates a complete response rate of 14.5% and partial response rate of 23.7%. Median overall survival is 14.9 months with progression-free survival of 7.3 months. Based on 4 studies, the most common serious adverse events include Grade 3-4 Neutropenia (19.2%), Grade 3-4 Thrombocytopenia (12.8%), Febrile Neutropenia (8.4%). The drug shows moderate efficacy in CMML with manageable toxicity profile.

## RAS Mutation Subgroup Analysis

- **RAS-mutated CMML**: 12.3% (PMID: 36455187)
- **Non-RAS-mutated CMML**: 18.7% (PMID: 40252309)

## Citations

- **PMID 36455187**: Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia
  - DOI: 10.1200/JCO.22.00437
  - Year: 2023

- **PMID 40252309**: Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure
  - DOI: 10.1016/j.leukres.2025.107692
  - Year: 2025

- **PMID 37548390**: Cox proportional hazards deep neural network identifies peripheral blood complete remission
  - DOI: 10.1002/ajh.27046
  - Year: 2023

- **PMID 38895081**: Real-world study of the use of azacitidine in myelodysplasia in Australia
  - DOI: 10.1002/jha2.911
  - Year: 2024

